Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CombinatoRx's drug CRx-102 for rheumatoid arthritis has produced positive results in a phase II clinical trial.
Subscribe to our email newsletter
CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and a low dose of the steroid prednisolone.
The trial compared CRx-102 plus a disease-modifying anti-rheumatic drug to placebo plus a disease-modifying anti-rheumatic drug in subjects with rheumatoid arthritis. In this trial, CRx-102 demonstrated statistically significant improvements on primary and secondary endpoints.
“The results observed with CRx-102 are more significant than what one would expect to see with prednisolone alone, and given that, may certainly be of clinical benefit,” said John Kirwan, Bristol Royal Infirmary, University of Bristol Rheumatology Unit in the UK.
CRx-102 has now demonstrated positive results in three clinical settings. In a previous study of hand osteoarthritis, CRx-102 demonstrated a statistically significant reduction in pain and stiffness. In a separate inflammatory biomarker study, CRx-102 demonstrated a statistically significant reduction in C-reactive protein.
The modified-release commercial formulation of CRx-102 is expected to be completed in 2007 and plans are underway to initiate a phase IIb study with CRx-102 in osteoarthritis.